Adma Biologics (ADMA) Non-Current Deffered Revenue (2011 - 2025)

Adma Biologics' Non-Current Deffered Revenue history runs 14 years deep, the most recent figure standing at $1.4 million for Q4 2025.

• Quarterly Non-Current Deffered Revenue fell 9.18% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 9.18% YoY) and the FY2025 annual result came in at $1.4 million, down 9.18% from the prior year.
• Non-Current Deffered Revenue was $1.4 million for Q4 2025 at Adma Biologics, down from $1.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $2.1 million in Q1 2021 and bottomed at $1.4 million in Q4 2025.
• A 5-year average of $1.7 million and a median of $1.7 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue decreased 6.42% — and 2025, when it decreased 9.18%.
• Adma Biologics' Non-Current Deffered Revenue stood at $2.0 million in 2021, then declined by 7.23% to $1.8 million in 2022, then dropped by 7.8% to $1.7 million in 2023, then fell by 8.46% to $1.5 million in 2024, then slipped by 9.18% to $1.4 million in 2025.
• Business Quant data shows ADMA's Non-Current Deffered Revenue at $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.5 million in Q2 2025.